DaVita 10-Q Details Q3 EPS of $3.40, $62M China Impairment and $862M of Buybacks
DVA sits 78% above its 52-week low of $101 on elevated volume (2.5× avg).
Summary
DaVita's Q3 2026 10-Q shows net income of $222.9 million ($3.40 diluted) on $3.578 billion of revenue, with a $62.2 million China impairment and $862.5 million of year-to-date buybacks.
Key Events · Earnings and Guidance · DVA
-
Q3 EPS Jumps to $3.40
Net income attributable to DaVita was $222.931 million, or $3.40 diluted, versus $150.332 million ($2.04) in Q3 2025; revenue rose to $3.578 billion from $3.420 billion.
-
$62M China Impairment Hits Operating Income
Goodwill and other asset impairment charges of $62.176 million in the China reporting unit, of which $31.597 million was allocated to noncontrolling interests, pulled operating income to $499.255 million from $505.767 million a year earlier.
-
Cash Flow and Buybacks
Nine-month operating cash flow was $1.330 billion and free cash flow $672 million; the company repurchased 5.837 million shares for $862.525 million, leaving $1.212 billion authorized as of October 27, 2026.
-
CEO 10b5-1 Sale Plan Adopted
CEO Javier Rodriguez adopted a Rule 10b5-1 trading arrangement on September 7, 2026 covering up to 115,810 shares for sale between December 8, 2026 and August 26, 2027.
Analysis · DVA · Industrial Applications And Services
The 10-Q puts hard numbers behind this morning's Q3 headline. Net income attributable to DaVita rose to $222.9 million, or $3.40 diluted, from $150.3 million ($2.04) a year earlier, on revenue of $3.578 billion versus $3.420 billion. The quarter absorbed a $62.2 million goodwill and asset impairment in the China reporting unit, driven by adverse reimbursement rate changes in non-renal hospital services, which cut operating income to $499 million from $506 million a year ago even as revenue grew. Nine-month operating cash flow of $1.330 billion funded $862.5 million of buybacks, and $1.212 billion of authorization remains, so the capital-return program is still running at scale. The China unit remains at risk of further impairment.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DVA was trading at $180.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.3B. The 52-week trading range was $101.00 to $247.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.